(marketscreener.com) SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion , the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services , which is the first time Recursion has been ranked by...https//www.marketscreener.com/quote/stock/RECURSION-PHARMACEUTICALS-121456074/news/Recursion-Receives-ISS-ESG-Prime-Rating-and-Plans-to-Participate-in-the-Goldman-Sachs-Global-Sustain-41352908/?utm_medium=RSS&utm_content=20220818

Virtus ETF Advisers LLC Purchases 8,405 Shares of Recursion Pharmaceuticals, Inc. (NASDAQRXRX)

Recursion Pharmaceuticals, Inc. (NASDAQRXRX – Get Rating) COO Tina Marriott Larson sold 16,000 shares of the business’s stock in a transaction dated Thursday, September 29th. The shares were sold at an average price of $10.86, for a total value of $173,760.00. Following the sale, the chief operating officer now directly owns 205,107 shares of the […]

Recursion Pharmaceuticals, Inc. (NASDAQRXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of the firm’s stock in a transaction dated Thursday, December 29th. The shares were sold at an average price of $7.70, for a total value of $61,600.00. Following the completion of the sale, the chief operating officer now directly owns 203,654 […]

Victory Capital Management Inc. purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQRXRX – Get Rating) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 12,062 shares of the company’s stock, valued at approximately $128,000. Several other institutional investors also recently added to or reduced their stakes in […]

Recursion Pharmaceuticals, Inc. (NASDAQRXRX – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $9.10, but opened at $9.37. Recursion Pharmaceuticals shares last traded at $9.35, with a volume of 664 shares changing hands. Analyst Upgrades and Downgrades A number of research analysts have commented on […]

Wirkstoffforschung mit künstlicher Intelligenz Durch die Zusammenarbeit sollen neue Therapien für Herz- und Lungenerkrankungen entwickelt werden.

Recursion Pharmaceuticals, Inc. (NASDAQRXRX) Director Blake Borgeson Sells 8,885 Shares

Recursion Pharmaceuticals Not Yet Derisking Drug Development With AI

(marketscreener.com) SALT LAKE CITY, Nov. 2, 2022 /PRNewswire/ -- Recursion , the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences Credit...https//www.marketscreener.com/quote/stock/RECURSION-PHARMACEUTICALS-121456074/news/Recursion-to-Participate-in-Upcoming-Investor-Conferences-42177150/?utm_medium=RSS&utm_content=20221102

FY2022 EPS Estimates for Recursion Pharmaceuticals, Inc. (NASDAQRXRX) Reduced by SVB Leerink

Victory Capital Management Inc. purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQRXRX – Get Rating) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 12,062 shares of the company’s stock, valued at approximately $128,000. Several other institutional investors also recently added to or reduced their stakes in […]

ProShare Advisors LLC cut its holdings in Recursion Pharmaceuticals, Inc. (NASDAQRXRX – Get Rating) by 26.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,950 shares of the company’s stock after selling 10,157 shares during the period. ProShare Advisors LLC’s holdings in Recursion Pharmaceuticals were worth […]

Recursion Pharmaceuticals, Inc. (NASDAQRXRX) CEO Sells $136,715.00 in Stock

Recursion Pharmaceuticals (NASDAQRXRX – Get Rating) had its price objective upped by The Goldman Sachs Group from $7.00 to $8.00 in a report published on Thursday morning, Marketbeat.com reports. They currently have a neutral rating on the stock. Separately, Bank of America lowered shares of Recursion Pharmaceuticals from a buy rating to a neutral rating […]

SVB Leerink Comments on Recursion Pharmaceuticals, Inc.’s Q3 2022 Earnings (NASDAQRXRX)

Recursion Pharmaceuticals Not Yet Derisking Drug Development With AI

Das US-Startup kooperiert mit dem deutschen Pharmakonzern. Außerdem Tesla-Rivale Lucid stellt sein erstes Modell vor und Softbank verliert zwölf Milliarden US-Dollar an Marktwert.

Recursion Pharmaceuticals Not Yet Derisking Drug Development With AI